ERS Genomics expands its CRISPR licensing footprint by providing KU Leuven's Viral Vector Core with essential intellectual property to advance global genome editing research services.
ERS Genomics expands its CRISPR licensing portfolio through a new agreement with KU Leuven.
KU Leuven gains access to foundational CRISPR/Cas9 IP to expand its genome editing services.
ERS Genomics has entered into a strategic licensing agreement with KU Leuven, granting the university's Viral Vector Core access to foundational CRISPR/Cas9 intellectual property. This partnership aims to bolster genome editing capabilities for both academic and commercial research entities on a global scale.
The agreement allows KU Leuven's Viral Vector Core to utilize ERS Genomics' foundational CRISPR/Cas9 intellectual property, enabling the institution to provide enhanced genome editing services to a global research client base.